No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PCRX240517P30000
- 0.90
- +0.20+28.57%
15min DelayClose May 10 15:59 ET
1.00High0.60Low
0.60Open0.70Pre Close63 Volume269 Open Interest30.00Strike Price5.00KTurnover55.01%IV-1.94%PremiumMay 17, 2024Expiry Date0.58Intrinsic Value100Multiplier6DDays to Expiry0.32Time Value100Contract SizeAmericanOptions Type-0.5903Delta0.1862Gamma25.58Leverage Ratio-0.0669Theta-0.0028Rho-15.10Eff Leverage0.0148Vega
Intraday
- 5D
- 1D
News
Express News | Pacira BioSciences Reveals Pricing Of $250.0M Aggregate Principal Amount Of 2.125% Convertible Senior Notes Due 2029
Express News | Pacira Convertible Senior Notes Maturity Set for May 15, 2029
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes Due 2029
PDF Version TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior no
Pacira Biosciences Announces Proposed Offering of $250M Aggregate Principal Amount of Convertible Senior Notes
Express News | Pacira Biosciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate princ
Comments
Recent insider share sale and lack of insider buying in the past year may concern investors. Despite some alignment between management and smaller shareholders, caution is advised due to recent insider selling activity.
Pacira BioSciences Independent Director Gary Pace Sells 85% Of Holding 1
Pacira BioSciences' moderate net income growth is seen as a positive despite a low ROE. The growth could be due to good management decisions or a low payout ratio, as it doesn't pay dividends. Analysts predict future earnings momentum.
1
Multiple insiders selling shares over the past year could be a red flag. However, insider ownership level shows alignment between management and smaller shareholders. Lack of insider purchases in the past year calls for caution.
The market seems to tolerate EPS decline but last year's worse-than-average performance may indicate long term investor concerns.
$Pacira BioSciences(PCRX.US$ $Flexion Therapeutics Inc(FLXN.US$ On October 12, Pacira BioSciences announced that it has entered into a definitive agreement to acquire Flexion Therapeutics For $8.50 per share, or approximately $430 million, in cash to enhance its non-opioid pain portfolio. The deal also includes contingent valuable rights worth up to $8.00 per share, which are tied to Zilretta sales targets and FDA approvals for FX201 and FX301.
3
Read more